---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-26-000017"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:56:23.345814+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows

## Summary
- Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).
- GAAP net loss $40.4M ($0.13/share) vs GAAP net income $2.4M in Q4 2024 (incl $154.4M debt restructuring gain).
- Non-GAAP net loss $37.6M ($0.12/share) vs $55.3M ($0.20) in Q4 2024; non-GAAP gross margin 40% vs 31%.
- Vega placements 42 in Q4 (140 FY); Revio placements 21 Q4 (61 FY). Annualized Revio pull-through ~$242,000.
- Completed sale of short-read assets for ~$48.1M net cash; cash & investments $279.5M at year end.

## SEC filing metadata
- accession: 0001299130-26-000017
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000017/0001299130-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000017/pacb-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-26-000017
- JSON: https://secwatch.observer/filing/0001299130-26-000017.json
- Plain text: https://secwatch.observer/filing/0001299130-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.